Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience

Background: Evaluating multiple biomarkers including human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) status, programed death-ligand 1 (PD-L1), and claudin 18.2 (CLDN18.2) is essential for selecting appropriate first-line therapy of metastatic gastroesophageal adenocarcinoma (m...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	U. Okazaki, I. Nakayama, N. Sakamoto, T. Kuwata, A. Kawazoe, M. Yoshida, M. Yura, Y. Matsubara, A. Jubashi, S. Sato, S. Ushiyama, Y. Miyashita, A. Kobayashi, T. Hashimoto, S. Mishima, D. Kotani, Y. Nakamura, Y. Kuboki, H. Bando, T. Kojima, T. Yoshino, T. Kinoshita, K. Shitara
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-09-01
Serier:	ESMO Gastrointestinal Oncology
Fag:	gastroesophageal adenocarcinoma immunohistochemistry biomarker personalized treatment clinical practice
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2949819824000475
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!